12 Meningococcal disease


  1. Meningococcal Disease Surveillance Group. 1976. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. Journal of Infectious Diseases 134(2): 201–4.
  2. Neal KR, Nguyen-Van-Jam J, Jeffrey N, et al. 2000. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. British Medical Journal 320(7238): 846.
  3. Bruce MG, Rosenstein NE, Capparella JM, et al. 2001. Risk factors for meningococcal disease in college students. Journal of the American Medical Association 286(6): 688–93.
  4. Nelson SJ, Charlett A, Orr HJ, et al. 2001. Risk factors for meningococcal disease in university halls of residence. Epidemiology and Infection 126(2): 211–17.
  5. Hahné SJ, Gray SJ, Aguilera N, et al. 2002. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. The Lancet 359(9306): 582–3.
  6. Lopez L, Sexton K. 2013. The Epidemiology of Meningococcal Disease in New Zealand in 2012. URL: (accessed 10 September 2013).
  7. Trotter CL, Chandra M, Cano R, et al. 2007. A surveillance network for meningococcal disease in Europe. FEMS Microbiological Reviews 31(1): 27–36.
  8. Vesikari T, Esposito S, Prymula R, et al. 2013. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. The Lancet 381(9869): 825–35.
  9. Centers for Disease Control and Prevention. 2015. Use of serogroup B meningococcal vaccines in persons aged ≥10 years at increased risk for serogroup B meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2015. Morbidity and Mortality Weekly Report 64(22). URL: (accessed 25 August 2015).
  10. Public Health England. 2015. Immunisation Against Meningococcal B Disease for Infants Aged from Two Months: Information for health professionals. URL: (accessed 17 July 2015).
  11. Sáfadi MAP, McIntosh EDG. 2011. Epidemiology and prevention of meningococcal disease: a critical appraisal of vaccine policies. Expert Review of Vaccines 10(12): 1717–30.
  12. Diez-Domingo J, Planelles-Cantarino MV, Baldo-Torrenti JM, et al. 2010. Antibody persistence 12 months after a booster dose of meningococcal-C conjugated vaccine in the second year of life. Pediatric Infectious Disease Journal 29(8): 768–70.
  13. Khatami A, Snape MD, John TM, et al. 2011. Persistence of immunity following a booster dose of Haemophilus influenzae type B-meningococcal serogroup C glycoconjugate vaccine: follow-up of a randomized controlled trial. Pediatric Infectious Disease Journal 30(3): 197–202.
  14. Tejedor JC, Merino JM, Moro M, et al. 2012. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine. Pediatric Infectious Disease Journal 31(10): 1074–7.
  15. Khatami A, Snape MD, Wysocki J, et al. 2012. Persistence of antibody response following a booster dose of Hib-MenC-TT glycoconjugate vaccine to five years: a follow-up study. Pediatric Infectious Disease Journal 31(10): 1069–73.
  16. Campbell H, Borrow R, Salisbury D, et al. 2009. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(Suppl 2): B20–9.
  17. Maiden MCJ, Stuart JM, for the UK Carriage Group. 2002. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. The Lancet 359(9320): 1829–31.
  18. Ramsay ME, Andrews NJ, Trotter CL, et al. 2003. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. British Medical Journal 326(7385): 365–6.
  19. Balmer P, Borrow R, Miller E. 2002. Impact of meningococcal C conjugate vaccine in the UK. Journal of Medical Microbiology 51(9): 717–22.
  20. Centers for Disease Control and Prevention. 2013. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports 62(2). URL: (accessed 27 September 2013).
  21. MacNeil JR, Cohn AC, Zell ER, et al. 2011. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatric Infectious Disease Journal 30(6): 451–5.
  22. Rennels M, King J, Ryall R, et al. 2004. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatric Infectious Disease Journal 23(5): 429–35.
  23. Hedari CP, Khinkarly RW, Dbaibo GS. 2014. Meningococcal serogroups A, C, W-135, and Y tetanus conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infection and Drug Resistance 7. DOI: 10.2147/IDR.S36243 (accessed 25 August 2015).
  24. Granoff DM, Pelton S, Harrison LH. 2013. Meningococcal vaccines. In: Plotkin SA, Orenstein WA, Offit PA (eds). Vaccines (6th edition): Elsevier Saunders.
  25. De Wals P, Dionne M, Douville-Fradet M, et al. 1996. Impact of a mass immunization campaign against serogroup C meningococcus in the Province of Quebec, Canada. Bulletin of the World Health Organization 74(4): 407–11.
  26. De Wals P, Deceunick G, De Serres G, et al. 2005. Effectiveness of serogroup C meningococcal polysaccharide vaccine: results from a case-control study in Quebec. Clinical Infectious Diseases 40(8): 1116–22.
  27. Department of Health and Ageing. 2013. Meningococcal disease. The Australian Immunisation Handbook. Canberra, ACT: Department of Health and Ageing.
  28. Ministry of Health. 2012. National Guidelines for Vaccine Storage and Distribution. URL:
  29. Findlow H, Borrow R, Andrews N, et al. 2012. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatric Infectious Disease Journal 31(6): 616–22.
  30. Moss SJ, Fenton AC, Toomey J, et al. 2010. Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type b vaccine and a meningococcal group C conjugate vaccine at 2, 3, and 4 months of age. Clinical Vaccine and Immunology 17(3). DOI: 10.1128/CVI.00315-09 (accessed 18 November 2012).
  31. Arguedas A, Soley C, Loaiza C, et al. 2010. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 28(18): 3171–9.
  32. Gasparini R, Conversano M, Bona G, et al. 2010. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clinical and Vaccine Immunology 17(4): 537–44.
  33. Bryant KA, McVernon J, Marchant CD, et al. 2012. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers: a pooled analysis of randomized trials. Human Vaccines & Immunotherapeutics 8(8): 1036–41.
  34. Klein NP, Reisinger KS, Johnston W, et al. 2012. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatric Infectious Disease Journal 31(1): 64–71.
  35. American Academy of Pediatrics. 2012. Meningococcal infections. In: Pickering LK, Baker CJ, Kimberlin DW, et al (eds). Red Book: 2012 report of the Committee on Infectious Diseases (29th edition). Elk Grove Village, IL: American Academy of Pediatrics.
  36. Conterno LO, da Silva Filho CR, Ruggeberg JU, et al. 2006. Conjugate vaccines for preventing meningococcal C meningitis and septicaemia (Review). Cochrane Database of Systematic Reviews. Issue 3, Art. No. CD001834. DOI: 10.1002/14651858.CD001834.pub2 (accessed 20 August 2013).
  37. Pina LM, Bassily E, Machmer A, et al. 2012. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatric Infectious Disease Journal 31(11): 1173–83.
  38. Department of Health and Human Services, Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices (ACIP). 2010. Summary report. Meeting of the Advisory Committee on Immunization Practices, June 23–24. Atlanta, Georgia. URL: (accessed 15 January 2014).
  39. Diez-Domingo J, Albert A, Valdivieso C, et al. 1998. Adverse events after polysaccharide meningococcal A & C vaccine. Scandinavian Journal of Infectious Diseases 30(6): 636–8.
  40. Yergeau A, Alain L, Pless R, et al. 1996. Adverse events temporally associated with meningococcal vaccines. Canadian Medical Association Journal 154(4): 503–7.
  41. McCormick JB, Gusm HH, Nakamura S, et al. 1980. Antibody response to serogroup A & C meningococcal polysaccharide vaccines in infants born of mothers vaccinated during pregnancy. Journal of Clinical Investigation 65(5): 1141–4.
  42. Ministry of Health. 2012. Communicable Disease Control Manual 2012. URL:
  43. Simmons G, Jones N, Calder L. 2000. Equivalence of ceftriaxone and rifampicin in eliminating naso-pharyngeal carriage of serogroup B N. meningitidis. Journal of Antimicrobial Chemotherapy 45(6): 909–11.
  44. Schaad UB, Salam MA, Aujard Y, et al. 1995. Use of fluoroquinolones in pediatrics: consensus report of an International Society of Chemotherapy Commission. Pediatric Infectious Disease Journal 14(1): 1–9.
  45. Heymann DL (ed). 2008. Control of Communicable Diseases Manual (19th edition). Washington DC: American Public Health Association.